Cargando…

Bevacizumab Eligibility in Patients with Metastatic and Recurrent Cervical Cancer: A Retrospective Review

OBJECTIVE: Bevacizumab is approved for use in combination with chemotherapy for metastatic/recurrent cervical cancer (CC), with increased survival/response rates. However, use of bevacizumab is not always feasible or safe. The purpose of this study was to identify the percentage of metastatic/recurr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skelton, William Paul, Castagno, Jacqueline, Cardenas-Goicoechea, Joel, Daily, Karen, Yeung, Anamaria, Markham, Merry Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989046/ https://www.ncbi.nlm.nih.gov/pubmed/29887734 http://dx.doi.org/10.1177/1179554918779587

Ejemplares similares

Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy?
por: Carbajal-Mamani, Semiramis L., et al.
Publicado: (2020)

Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study
por: Carbajal-Mamani, Semiramis L., et al.
Publicado: (2020)

Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
por: Ercelep, Özlem, et al.
Publicado: (2020)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
por: He, Ying, et al.
Publicado: (2022)

Orbital metastasis of squamous cell cervical cancer: A case report and review of literature
por: Mendia, Ana, et al.
Publicado: (2020)

Langerhans cell sarcoma of the vulva: Case report and review of the literature
por: Tillit, Stephanie, et al.
Publicado: (2020)

Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
por: Isono-Taniguchi, Roze, et al.
Publicado: (2022)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence
por: Jackson, Matthew W, et al.
Publicado: (2014)

Eligibility for Bevacizumab as an Independent Prognostic Factor for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study
por: Takagi, Yusuke, et al.
Publicado: (2013)

Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits
por: Zamorano, Abigail S., et al.
Publicado: (2017)

Robotic assisted cytoreductive surgery, removal of a recurrent disease in the right pericaval lymph node in a patient with ovarian cancer with the robotic Xi platform
por: Shoraka, Massoud, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases
por: Isono-Nakata, Rose, et al.
Publicado: (2018)

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications
por: Li, Yi, et al.
Publicado: (2017)

The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study
por: Yu, Jiangtao, et al.
Publicado: (2019)

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
por: Devaux, Madeline, et al.
Publicado: (2019)

Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
por: Liu, Yanxin, et al.
Publicado: (2023)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Eligibility of real-world patients with metastatic breast cancer for clinical trials
por: Batra, Atul, et al.
Publicado: (2020)

Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2013)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
por: Mulcahy, Mary F
Publicado: (2008)

Case Report: Probable Cerebral Amyloid Angiopathy-Related Inflammation During Bevacizumab Treatment for Metastatic Cervical Cancer
por: Koudriavtseva, Tatiana, et al.
Publicado: (2021)

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
por: Mayenga, Marie, et al.
Publicado: (2023)

Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
por: Cohen, Adam L., et al.
Publicado: (2013)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
por: Ozaki, Kai, et al.
Publicado: (2021)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis
por: Tatineni, Swetha, et al.
Publicado: (2022)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Recurrent or primary metastatic cervical cancer: current and future treatments
por: Gennigens, C., et al.
Publicado: (2022)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Modeling Efficacy of Bevacizumab Treatment for Metastatic Colon Cancer
por: Islam, Rezwan, et al.
Publicado: (2013)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9pc3oov7ogbav35h4t0tsj8m61